Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK reports ‘important benefits’ of Seretide/Advair

GSK reports ‘important benefits’ of Seretide/Advair

11th June 2008

GlaxoSmithKline (GSK) has announced the results of a one-year study showing important benefits of Seretide/Advair Diskus in African American patients with asthma.

Seretide/Advair Diskus is a combination of salmeterol, a long-acting beta-agonist and fluticasone, an inhaled corticosteroid (ICS).

In the trial, the drug was compared to the use of an ICS, Flovent Diskus (fluticasone propionate inhalation powder), alone.

Patients receiving Seretide/Advair Diskus showed a lower rate of exacerbations, though this difference was not statistically significant.

Data published in Current Medical Research and Opinion revealed that patients receiving the drug showed improvements in lung function measures, reductions in daily symptom and rescue inhaler use and night-time awakenings.

William Bailey, lead author and director of the Lung Health Centre at the University of Alabama at Birmingham, said: “Uncontrolled asthma is a critical public health issue for African Americans and this research is reassuring for clinicians whose patients are not controlled on an ICS alone that treatment with salmeterol/fluticasone propionate helps improve day-to-day asthma control.”

He added that the improvement of lung function and prevention of exacerbations are key goals of asthma management.

In April 2008, GSK reported that Q1 sales of Seretide/Advair rose ten per cent on the figures for the first quarter of 2007.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.